Table 4.
Treatment Response and Outcomes
| Patient | Histology | Dose Level | Initial Clinical Stage | Pathologic Response Grade | Pathologic Stage | Status in follow-up |
|---|---|---|---|---|---|---|
| 1001 | Squamous cell carcinoma | 1 | T3N1 | TRG 1 | T0N0 | Fatal GI bleed, day #99 |
| 1002 | Adenocarcinoma | 1 | T3N1 | TRG 2 | T2N0 | NED at 50 months |
| 1003 | Adenocarcinoma | 1 | T2N0 | TRG 2 | T1aN0 | NED at 50 months |
| 2004 | Squamous cell carcinoma | 2 | T3N1 | TRG 1 | T0N0 | Recurrent at 19 months |
| 1005 | Signet cell carcinoma | 1 | T3N1 | TRG 1 | T0N0 | NED at 45 months |
| 1006 | Adenocarcinoma | 1 | T2N1 | TRG 1 | T0N0 | Recurrent at 11 months |
| 1007 | Adenocarcinoma | 1 | T3N1 | TRG 1 | T0N0 | NED at 40 months |
| 2008 | Adenocarcinoma | 2 | T3N3 | TRG 3 | T1bN3 | Recurrent at 11 months |
| 2009 | Adenocarcinoma | 2 | T3N0 | TRG 2 | T2N0 | NED at 32 months |